摘要
目的探讨瑞舒伐他汀治疗缺血性心肌病对心功能改善情况及治疗后相关炎性因子的变化。方法选取128例因心脏缺血事件导致慢性心功能不全(缺血性心肌病)患者,随机分为实验组和对照组,对照组64例,给予常规慢性心衰治疗,即β受体阻断剂、ACEI/ARB类药物、醛固酮受体拮抗剂,必要时加用地高辛及利尿剂;实验组64例,给予常规心衰治疗基础上,加用瑞舒伐他汀。观察2组患者治疗6个月后心功能改善以及相关炎症指标的情况。结果两组比较,实验组心功能指标(分级、左室射血分数LVEF、左室舒张末内径LVEDd、左心室后壁厚度LVPWT、6 min步行试验6MWT、BNP)、炎症相关指标(C反应蛋白CRP、低密度脂蛋白LDL-C)等情况均明显优于对照组(P<0.05)。结论瑞舒伐他汀能降低缺血性心肌病患者再次住院率,对其心功能有改善作用且能显著降低炎性因子活化。
Objective To investigate the changes and effect of atorvastatin on cardiac function and inflammatory factors in patients with ischemic cardiomyopathy.Methods 128 patients with ischemic cardiomyopathy were randomly divided into experimental group and control group,64 cases in each group.The control group was given the routine treatment of chronic heart failure（ βblockers,ACEI / ARB,aldosterone receptor antagonist,if necessary with digoxin and diuretic）.The experimental group was given the Rosuvastatin on the basis of the routine heart failure treatment. The readmission rates,improvement of cardiac function and inflammation factors in the two groups were observed after a half year.Results The readmission rates,cardiac function index（ the grade,left ventricular ejection fraction LVEF,left ventricular end diastolic diameter LVEDd,left ventricular posterior wall thickness LVPWT,6 minutes Walk test 6MWT,BNP） and inflammatory factors（ C-reactive protein CRP,low density lipoprotein LDL-C） in the experimental group were significantly better than those in the control group（ P〈0. 05）. Conclusion the Rosuvastatin can reduce the readmission rates and inflammatory factors in the patients with ischemic cardiomyopathy and improve the cardiac functions.
出处
《湖北民族学院学报（医学版）》
2016年第4期20-22,共3页
Journal of Hubei Minzu University(Medical Edition)
关键词
瑞舒伐他汀
缺血性心肌病
心功能
炎性因子
rosuvastatin
ischemic cardiomyopathy
cardiac function
inflammatory factors
